Calcitonin gene-related peptide (CGRP) is the most potent endogenous vasodilatory peptide, and is involved in the regulation of blood flow to vital organs. We have previously shown that CGRP may be involved in vascular adaptations that occur during pregnancy, and that steroid hormones may be involved in these mechanisms. We hypothesized that endogenous CGRP is required for maintaining blood pressure and fetoplacental growth in pregnant rats, and that progesterone will enhance CGRP effects. The vasodilatory effects of CGRP are known to be inhibited by a competitive CGRP receptor antagonist, the C-terminal fragment CGRP 8-37 . In the present study, we investigated whether continuous s.c. infusion of CGRP 8-37 to pregnant rats will reduce fetoplacental growth and increase systolic blood pressure. We also assessed whether progesterone will alter the effects of CGRP 8-37 on blood pressure during postpartum. Groups of five pregnant rats were s.c. infused with varying doses of CGRP 8-37 from Day 17 of pregnancy. Daily systolic blood pressures, pup weight, mortality at term delivery, and fetoplacental weights on Day 20 of gestation were measured. CGRP 8-37 at a dose of 0.083 mg day Ϫ1 kg Ϫ1 body weight (BW) showed no effects; however, doses of 0.33 and 1.33 mg day Ϫ1 kg Ϫ1 BW increased (P Ͻ 0.05) blood pressure during pregnancy, and these elevated blood pressures persisted during postpartum with the highest dose used. Progesterone (2 mg per injection, twice a day; s.c.) treatment significantly elevated blood pressure in rats infused with CGRP 8-37 during postpartum, suggesting that progesterone regulates CGRP-induced vascular effects. CGRP 8-37 infusion caused significant reductions in pup weight with an increase in mortality rate, and these effects were dose-dependent. Placental and fetal weights were also decreased prior to term on Day 20 of gestation, 72 h after CGRP 8-37 infusion, indicating effects on uteroplacental tissues. Therefore, we suggest that endogenous CGRP plays an important role in maintaining normal fetoplacental development, fetal survival, and vascular adaptations during pregnancy. placenta, pregnancy, progesterone, uterus
INTRODUCTION
Calcitonin gene-related peptide (CGRP), a 37-amino acid neuropeptide, is the most potent vasodilator known to date [1] . CGRP is produced by the tissue-specific alterna- tive splicing of the primary transcript of the calcitonin/ CGRP gene [2] and is synthesized almost exclusively in neuronal tissues [3, 4] ; however, trace amounts were sometimes detectable in thyroid [5] . Indeed, it has been reported that circulating CGRP is synthesized in dorsal root ganglia, transported through the axons, and released at perivascular nerve terminals. The role of CGRP in the regulation of systemic and regional hemodynamics by virtue of its potent vasodilator activity has been reported [6, 7] .
Pregnancy and female reproductive hormones profoundly influence the vascular system. Several studies suggest that estrogens increase vascular relaxation and maintain blood pressure homeostasis, perhaps through induction of nitric oxide synthesis in endothelial cells [8] [9] [10] . Studies by Rylance et al. [11] demonstrated that progesterone (P 4 ) reduces blood pressure. Recent studies from our laboratory demonstrated that vascular relaxation responses to CGRP were enhanced during pregnancy and with estrogen (E 2 ) and P 4 treatments in ovariectomized rats [12] . Decreases in CGRP-induced total vascular resistance were substantially greater in pregnant rats and in ovariectomized rats treated with E 2 ϩ P 4 [13] . Furthermore, both pregnancy and E 2 ϩ P 4 treatment in ovariectomized rats enhanced the effects of CGRP on vascular resistance in mesenteric, coronary, and renal vasculature [13] . The effects of CGRP on reducing blood pressure in N G -nitro-L-arginine methyl ester (L-NAME), an inhibitor of nitric oxide-induced hypertension, were greater during pregnancy and with P 4 treatment during postpartum [14] . These data collectively suggest that vasodilator effects of CGRP are increased during pregnancy and that the female sex steroid hormones appear to regulate these effects.
Administration of CGRP reversed hypertension and fetal mortality induced by L-NAME in pregnant rats [15, 16] , indicating that CGRP can compensate for a perturbed nitric oxide system. Further, an acute bolus injection of CGRP , a potent and specific CGRP receptor antagonist, produced a significant increase in mean arterial blood pressure in rats treated with L-NAME during pregnancy [14] . The mechanism of this effect appears to be an enhanced vascular responsiveness to CGRP during pregnancy. However, it is unknown whether continuous infusion of CGRP would elevate blood pressure during pregnancy and adversely affect fetoplacental growth.
Pregnancy is associated with an increase in uteroplacental blood flow and a decrease in uterine vascular resistance [17, 18] . Previous studies demonstrated that the effects of CGRP in isolated uterine vascular bed preparation were substantially increased in ovariectomized rats when they were treated with sex-steroid hormones [19] . Potent vasodilatory effects of CGRP were also reported in the uterine artery of sheep [20] and humans [21, 22] , and the effects in women are significantly greater during pregnancy. Firth et al. [23] showed that CGRP relaxes human chorionic plate vasculature. Studies by Mandsager et al. [24] using perfused placental cotyledons from term pregnant women showed that CGRP is a potent vasodilator in placenta. These studies suggest a beneficial role for CGRP in uteroplacental vascular function.
In the present studies, we hypothesized that endogenous CGRP plays an important role in maintaining normal fetoplacental development and vascular adaptations during pregnancy. Further, we assessed whether CGRP-related vascular adaptations are P 4 -dependent. Studies were, therefore, designed to examine the effects of continuous infusion of CGRP , a CGRP receptor antagonist, to pregnant rats on fetoplacental growth, fetal survival, and blood pressure. Because P 4 levels are low in postpartum rats compared with levels during pregnancy [25] , and because the role of this hormone in modulating the effect of CGRP 8-37 on blood pressure is not known, we investigated whether P 4 treatment enhances CGRP effects on blood pressure during postpartum.
MATERIALS AND METHODS
Adult virgin, timed, pregnant (300 g body weight [BW]) rats were purchased from Harlan Sprague-Dawley (Houston, TX) and were received in our animal care and use facility on Day 14 of pregnancy (Day 1 equals the day of positive sperm smear). All animals were given free access to food and water. The Animal Care and Use Committee of the University of Texas Medical Branch approved all procedures.
Experimental Protocol
Fetal growth in rats accelerated starting at Day 17 of gestation [26] . Therefore, groups of Day 17 pregnant rats (n ϭ 5) were s.c. infused through osmotic minipumps (Alza, Palto Alto, CA) with a pumping rate of 5 l/h, with varying doses of CGRP receptor antagonist, CGRP (0.083-1.33 mg day Ϫ1 kg Ϫ1 BW) in saline, or with saline only. Dosages of CGRP were chosen on the basis of their effects on blood pressure in our previous studies [14] . We have previously infused CGRP at Day 17 of gestation to Postpartum Day 6 and found significant effects on blood pressure reduction during pregnancy and postpartum, and improved fetal growth and survival [16, 27] . These studies demonstrate the stability of CGRP peptides in saline in minipumps for an extended period of time. Furthermore, integrity of this antagonist recovered from the minipumps was maintained up to 14 days using mass spectrometry (data not shown).
In the second experiment, groups of five pregnant rats were s.c. infused through osmotic minipumps filled with CGRP 8-37 (0.33 mg day Ϫ1 kg Ϫ1 BW) in saline or saline only beginning at Day 17 of gestation. After spontaneous delivery of pups on Day 22 of pregnancy, the CGRP 8-37 group received P 4 treatments (2 mg/rat in 0.2 ml of sesame oil twice daily, s.c.) from Postpartum Day 1 to Day 6. Controls received oil only. In both experiments, systolic blood pressures were measured daily by the pneumatic tail cuff method (Narco-Biosystems, Houston, TX). After restraining, the rats were allowed to stabilize. Three consecutive measurements (10-sec intervals) were obtained and these values were averaged for each animal. All measurements were made at the same time of day. In animals that delivered spontaneously, pup weight and mortality were recorded immediately (within 1 h).
To determine the effects of CGRP 8-37 on fetal growth and placental development before labor, CGRP (1.33 mg day Ϫ1 kg Ϫ1 BW) was continuously infused s.c. from Day 17 of gestation, and animals were killed on Day 20 of gestation. In these animals, placentae and fetuses were isolated, blotted to remove fluids and blood, and immediately weighed.
Human CGRP receptor antagonist, CGRP , was synthesized by the use of solid-phase t-butoxycarbonyl chemistry by one of the authors (S.J.W.), purified, and characterized by mass spectrometry, amino acid analysis, and sequencing. Progesterone was purchased from Sigma Chemical Company (St. Louis, MO).
Statistical Analysis
The weight (in grams) of fetuses, placentae, and pups are expressed as means Ϯ SEM and compared using ANOVA or the Student t-test. Fetal and pup mortality were compared using the chi-square test. Systolic blood pressures (mm Hg) were analyzed using repeated measures ANOVA for comparing changes across all days, with an exchangeable covariance structure for the factors of treatment group, day, and treatment ϫ day interaction. In all analyses, P Ͻ 0.05 was considered statistically significant. on Systolic Blood Pressure in Rats During Pregnancy and Postpartum Figure 1 shows longitudinal changes in systolic blood pressure in rats during pregnancy from Day 17 of gestation to Day 6 postpartum. CGRP (0.083-1.33 mg day Ϫ1 kg Ϫ1 BW) was continuously infused from Day 17 of pregnancy to postpartum Day 6, and blood pressures were measured daily to assess whether the effects of CGRP were decreased during the postpartum period, when serum P 4 levels were expected to be minimal (Fig. 1 ). Blood pressure increases following infusion of CGRP ) on systolic blood pressure in CGRP (0.33 mg day Ϫ1 kg Ϫ1 BW)-infused postpartum rats. CGRP was infused beginning on Day 17 of pregnancy through osmotic minipumps. From Day 1 postpartum until Postpartum Day 6, progesterone (2 mg per injection, twice daily) was injected into five animals receiving CGRP . Values are expressed as means Ϯ SEM for five animals in each group. *P Ͻ 0.05, CGRP 8-37 ϩ progesterone versus CGRP . (0.083-1.33 mg day Ϫ1 kg Ϫ1 BW) on pup weights (A) and mortality rate (B) at term after spontaneous delivery in rats. CGRP was s.c. infused through osmotic minipumps from Day 17 of gestation, and pup weights and mortality rates were assessed after spontaneous delivery, within 1 h. Values are means Ϯ SEM; n ϭ 5 rats/group. *P Ͻ 0.05 vs. control (saline infusion). rats (Fig. 2) . Small increases in blood pressure were persistent with CGRP 8-37 at 0.33 mg day Ϫ1 kg Ϫ1 BW from Postpartum Day 4 to Postpartum Day 6. However, administration of P 4 to rats treated with CGRP 8-37 rats substantially increased the blood pressure beginning from Postpartum Day 3 until Postpartum Day 6.
RESULTS
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FIG. 3. Effects of varying doses of CGRP
Effects of Infusion of CGRP 8-37 During Pregnancy on Pup Weight and Mortality
We assessed the role of endogenous CGRP on pregnancy outcome by continuously infusing CGRP from Day 17 of gestation. The animals were closely monitored throughout the infusion period, and none of the animals delivered prematurely. All animals delivered spontaneously at term. Figure 3 shows the changes in pup weight and pup mortality when CGRP (0.083-1.33 mg day Ϫ1 kg Ϫ1 BW) was infused compared with those of saline-treated rats. Mortality rate and the weight of pups were both unchanged in rats receiving 0.083 mg day Ϫ1 kg Ϫ1 BW. However, the weight of pups in rats receiving 0.33 and 1.33 mg day Ϫ1 kg Ϫ1 BW were substantially (P Ͻ 0.05) lower than saline-treated controls. In these animals, the mortality rate of pups was also significantly (P Ͻ 0.05) increased. The differences in pup weights and mortality rate among rats that received CGRP at 0.33 and 1.33 mg day Ϫ1 kg Ϫ1 BW were not significant.
Effects of CGRP 8-37 Infusion During Pregnancy on Fetal and Placental Weights
To further assess whether the effects of CGRP 8-37 on fetal growth, fetal mortality, and placental weights could be detected before term on Day 20 of gestation, we infused CGRP (1.33 mg day Ϫ1 kg Ϫ1 BW) beginning on Day 17 of gestation. The animals were killed 72 h later and the fetal weights, placental weights, and fetal deaths were recorded. Figure 4 shows that CGRP 8-37 substantially decreased both placental (Fig. 4A) and fetal (Fig. 4B) weights compared with those of controls. CGRP infusion also caused increases in the percentages of dead fetuses compared with age-matched controls (Fig. 4C) .
DISCUSSION
In this study, we describe the effects of CGRP , a receptor antagonist for CGRP, on systolic blood pressure, fetoplacental growth, and fetal and pup mortality. We also investigated the effects of administration of exogenous P 4 to CGRP 8-37 -induced increases on blood pressure in postpartum rats. Chronic infusion of CGRP from Day 17 of gestation (the beginning of the rapid fetal growth phase) caused an elevation in systolic blood pressure during pregnancy, reduced fetoplacental growth, and increased pup mortality. These effects of CGRP on systolic blood pressure, and on pup weight and mortality, were significant with 0.33 and 1.33 mg day Ϫ1 kg Ϫ1 BW doses but not with the 0.083 mg dose. Elevated blood pressure persisted during postpartum, with the highest dose (1.33 mg) used, and with the 0.33 mg dose, the elevated blood pressure was observed only up to Day 2 of postpartum. Furthermore, when P 4 was injected in postpartum animals that received the 0.33 mg day Ϫ1 kg Ϫ1 BW dose of CGRP , systolic blood pressure was significantly elevated. Infusion of CGRP decreased the pup weight and increased pup mortality without altering gestational length. Both placental and fetal weights were reduced within 72 h of CGRP infusion to pregnant rats. These data suggest that endogenous CGRP may play a potent vasodilator role in both reproductive and nonreproductive vascular systems, and in maintaining normal fetoplacental development.
The role of endogenous CGRP in the regulation of blood pressure during pregnancy is not well understood. CGRP is widely distributed in the central and peripheral nervous systems in mammals [3, 4] . Circulatory CGRP levels increase FIG. 4 . Effects of CGRP antagonist, CGRP (1.33 mg day Ϫ1 kg Ϫ1 BW) on placental (A) and fetal (B) weights. Fetal mortality (C) was measured before term on Day 20 of gestation. CGRP 8-37 administered s.c. through osmotic minipumps starting on Day 17 of gestation, and tissues were collected 72 h later. Each bar represents the mean Ϯ SEM for four to six rats in each group. *P Ͻ 0.01 compared with controls.
during pregnancy and decrease after delivery in rats and humans [28] [29] [30] . Several reports from radio ligand and functional studies indicate that CGRP 8-37 is a competitive inhibitor of CGRP binding [31, 32] . Intravenous bolus administration of CGRP caused inhibition of hypotensive and vasodilator effects of exogenously administered CGRP in rats [33] [34] [35] . Studies by Hughes and Brain [36] demonstrated that CGRP was able to inhibit increases in blood flow in response to capsaicin, an agent that stimulates the release of CGRP from sensory nerve terminals. Furthermore, an increase in skin blood flow by CGRP was blocked by CGRP . However, no studies reported to date have examined the continuous infusion of this receptor antagonist either on blood pressure or on fetal growth. For the first time in the present study, we show that CGRP elevated systolic blood pressure during pregnancy (Fig. 1) , suggesting a role for endogenous CGRP for maintaining normal blood pressure during pregnancy.
Circulatory levels of P 4 increase during pregnancy compared to the nonpregnant state. Progesterone levels decline at the end of gestation, with the lowest levels being reached during postpartum [25] . Therefore, the postpartum period serves as a good control for low P 4 levels. Because the 0.33 mg CGRP dose was sufficient to cause increases in systolic blood pressure during pregnancy, we used this dose to assess whether P 4 alters the effects of this antagonist on vascular tone during postpartum. Administration of P 4 to postpartum rats caused elevated blood pressure when 0.33 mg day Ϫ1 kg Ϫ1 BW of CGRP was infused (Fig. 2) . The mechanisms involved in the ability of P 4 to alter CGRP effects are not addressed in this study. However, it is possible that P 4 may up-regulate CGRP receptors in the blood vessels, and therefore, CGRP may block the effects of endogenous CGRP on blood pressure in postpartum rats. Moreover, the systolic blood pressure in control animals appear to increase immediately postpartum (Days 1 and 2) compared with Day 17 of pregnancy (Fig. 1) , which is consistent with previous findings reported by Liao et al. [37] . These studies suggest that decreases in steroid hormone concentrations (pregnant vs. postpartum) may increase blood pressure in postpartum rats. Several lines of evidence suggest that elevated levels of female sex steroid hormones may play a beneficial role in maintaining vascular adaptations during pregnancy through several locally produced vasoactive agents. The studies by Grewal et al. [19] demonstrated that mean arterial blood pressure was decreased by a bolus injection of CGRP in the presence of estradiol-17␤ (E 2 ) and P 4 in nonpregnant, ovariectomized rats. We recently reported [12] that female sex steroid hormones significantly elevated vascular relaxation sensitivity to CGRP. Progesterone regulates the blood pressure-lowering effects of CGRP in L-NAME-induced hypertension in postpartum and nonpregnant ovariectomized rats [27] . It has been reported that CGRP receptors are gestationally regulated in rats in both uterus and in resistance blood vessels [38, 39] . These studies, together with our current findings, suggest that P 4 appears to regulate endogenous CGRP effects on the vascular system during pregnancy and postpartum, perhaps through the regulation of its receptor levels.
We next examined whether inhibition of endogenous CGRP by CGRP would inhibit fetoplacental growth and decrease pup survival. These data for the first time show that chronic infusion of CGRP dose-dependently (Fig.  3) causes fetal growth retardation and increases mortality, similar to the effects we reported with L-NAME treatment [16] . Further, the effects of CGRP on pup weight and mortality observed in our studies appeared to occur within 72 h after the start of CGRP infusion. Placental weights were significantly reduced in CGRP -treated rats in parallel with fetal weights, when examined on Day 20 of gestation (Fig. 4) . The detailed mechanisms through which CGRP 8-37 caused fetoplacental growth retardation are not addressed in this study. However, we suggest that this could occur by decreasing uterine blood flow. Recent reports indicate CGRP decreases uterine vascular resistance in rats [19] and that the uterine artery relaxation sensitivity to CGRP was higher in pregnant women than in nonpregnant women [21, 22] and rats [40] . Potent vasodilatory effects of CGRP were also reported for sheep uterine artery [20] . A reduction in placental weights during CGRP infusion further suggests that a reduction in uterine blood flow, resulting in placental growth being compromised in these animals. Reduced placental growth could then lead to fetal weight reductions. Moreover, CGRP has been reported to relax chorionic plate vasculature [23] and to decrease perfusion pressure in placental cotyledons [24] in humans. CGRP binding sites in placenta have been previously reported [41] . Therefore, it is possible that CGRP interfered with endogenous CGRP effects on uterine artery relaxation; therefore, reduced uteroplacental blood flow results in fetal growth retardation.
We and others have previously reported that CGRP is not only a vasodilator, but also a potent uterine smooth muscle relaxant in both rats [42] and humans [43, 44] . In fact, the uterine relaxation sensitivity to CGRP was substantially increased during pregnancy and decreased at term on Day 22 before labor, implicating a role for this peptide in maintaining uterine quiescence during pregnancy [42] . In the current study, infusion of CGRP from Day 17 of gestation failed to produce preterm labor. Thus, we suggest that inhibition of the uterine relaxant, CGRP alone, may not induce labor and that initiation of labor may require additional events to occur simultaneously, such as higher levels of contractile-associated proteins [45] .
In summary, inhibition of endogenous CGRP through continuous infusion of CGRP during pregnancy caused increases in systolic blood pressure together with fetal growth retardation and increased fetal mortality, and that these effects were dose-dependent. Progesterone modulates CGRP effects on blood pressure in postpartum rats. The detrimental effects of CGRP on fetal growth and survival occurred in parallel with the effects on placental weight, indicating that uteroplacental function is compromised in these animals, perhaps through decreases in uterine blood flow. These studies suggest that endogenous CGRP plays an important role in maintaining normal fetoplacental development and vascular adaptations during pregnancy, and that this may be mediated by progesterone. The one or more mechanisms responsible for these adaptations could be due to an increase in CGRP-induced vascular relaxation both in uterine and resistance blood vessels in pregnant rats.
